{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T20:15:45Z","timestamp":1781554545570,"version":"3.54.5"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,11,16]],"date-time":"2023-11-16T00:00:00Z","timestamp":1700092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,11,16]],"date-time":"2023-11-16T00:00:00Z","timestamp":1700092800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Lung"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1007\/s00408-023-00656-0","type":"journal-article","created":{"date-parts":[[2023,11,16]],"date-time":"2023-11-16T19:03:30Z","timestamp":1700161410000},"page":"617-624","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Methotrexate Polyglutamate Concentrations as a Possible Predictive Marker for Effectiveness of Methotrexate Therapy in Patients with Sarcoidosis: A Pilot Study"],"prefix":"10.1007","volume":"201","author":[{"given":"Montse","family":"Janssen Bon\u00e1s","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janani","family":"Sundaresan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth G. M.","family":"Keijsers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduard A.","family":"Struys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bas J. M.","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivienne","family":"Kahlmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlies S.","family":"Wijsenbeek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurits C. F. J.","family":"de Rotte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan C.","family":"Grutters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel","family":"Veltkamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,16]]},"reference":[{"key":"656_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2017.11.030","author":"KC Patterson","year":"2018","unstructured":"Patterson KC, Chen ES (2018) The pathogenesis of pulmonary sarcoidosis and implications for treatment. Chest. https:\/\/doi.org\/10.1016\/j.chest.2017.11.030","journal-title":"Chest"},{"key":"656_CR2","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1016\/S0140-6736(13)60680-7","volume":"383","author":"D Valeyre","year":"2014","unstructured":"Valeyre D, Prasse A, Nunes H et al (2014) Sarcoidosis. The Lancet 383:1155\u20131167. https:\/\/doi.org\/10.1016\/S0140-6736(13)60680-7","journal-title":"The Lancet"},{"key":"656_CR3","doi-asserted-by":"publisher","first-page":"2004079","DOI":"10.1183\/13993003.04079-2020","volume":"58","author":"RP Baughman","year":"2021","unstructured":"Baughman RP, Valeyre D, Korsten P et al (2021) ERS clinical practice guidelines on treatment of sarcoidosis. Eur Respir J 58:2004079. https:\/\/doi.org\/10.1183\/13993003.04079-2020","journal-title":"Eur Respir J"},{"key":"656_CR4","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1186\/s12890-020-01290-9","volume":"20","author":"V Kahlmann","year":"2020","unstructured":"Kahlmann V, Janssen Bon\u00e1s M, Moor CC et al (2020) Design of a randomized controlled trial to evaluate effectiveness of methotrexate versus prednisone as first-line treatment for pulmonary sarcoidosis: the PREDMETH study. BMC Pulm Med 20:271. https:\/\/doi.org\/10.1186\/s12890-020-01290-9","journal-title":"BMC Pulm Med"},{"key":"656_CR5","doi-asserted-by":"publisher","DOI":"10.1007\/s12350-022-03171-6","author":"R Vis","year":"2023","unstructured":"Vis R, Mathijssen H, Keijsers RGM et al (2023) Prednisone vs methotrexate in treatment na\u00efve cardiac sarcoidosis. J Nucl Cardiol. https:\/\/doi.org\/10.1007\/s12350-022-03171-6","journal-title":"J Nucl Cardiol"},{"key":"656_CR6","doi-asserted-by":"publisher","first-page":"278","DOI":"10.2174\/138920011795101840","volume":"12","author":"P Castaldo","year":"2011","unstructured":"Castaldo P, Magi S, Nasti AA et al (2011) Clinical pharmacogenetics of methotrexate. Curr Drug Metab 12:278\u2013286. https:\/\/doi.org\/10.2174\/138920011795101840","journal-title":"Curr Drug Metab"},{"key":"656_CR7","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1517\/14622416.5.7.819","volume":"5","author":"M Krajinovic","year":"2004","unstructured":"Krajinovic M, Moghrabi A (2004) Pharmacogenetics of methotrexate. Pharmacogenomics 5:819\u2013834. https:\/\/doi.org\/10.1517\/14622416.5.7.819","journal-title":"Pharmacogenomics"},{"key":"656_CR8","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1182\/blood.V93.5.1677","volume":"93","author":"MG Rots","year":"1999","unstructured":"Rots MG, Pieters R, Peters GJ et al (1999) Role of folylpolyglutamate synthetase and folylpolyglutamate hydrolase in methotrexate accumulation and polyglutamylation in childhood leukemia. Blood 93:1677\u20131683","journal-title":"Blood"},{"key":"656_CR9","doi-asserted-by":"publisher","first-page":"2200879","DOI":"10.1183\/13993003.00879-2022","volume":"61","author":"M Humbert","year":"2023","unstructured":"Humbert M, Kovacs G, Hoeper MM et al (2023) 2022 ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 61:2200879. https:\/\/doi.org\/10.1183\/13993003.00879-2022","journal-title":"Eur Respir J"},{"key":"656_CR10","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1378\/chest.12-1728","volume":"144","author":"ADM Vorselaars","year":"2013","unstructured":"Vorselaars ADM, Wuyts WA, Vorselaars VMM et al (2013) Methotrexate vs azathioprine in second-line therapy of sarcoidosis. Chest 144:805\u2013812. https:\/\/doi.org\/10.1378\/chest.12-1728","journal-title":"Chest"},{"key":"656_CR11","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1093\/rheumatology\/28.5.422","volume":"28","author":"M Tishler","year":"1989","unstructured":"Tishler M, Caspi D, Graff E et al (1989) Synovial and serum levels of methotrexate during methotrexate therapy of rheumatoid arthritis. Br J Rheumatol 28:422\u2013423. https:\/\/doi.org\/10.1093\/rheumatology\/28.5.422","journal-title":"Br J Rheumatol"},{"key":"656_CR12","doi-asserted-by":"publisher","first-page":"3299","DOI":"10.1002\/art.24034","volume":"58","author":"JM Dalrymple","year":"2008","unstructured":"Dalrymple JM, Stamp LK, O\u2019Donnell JL et al (2008) Pharmacokinetics of oral methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 58:3299\u20133308. https:\/\/doi.org\/10.1002\/art.24034","journal-title":"Arthritis Rheum"},{"key":"656_CR13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0208534","author":"MCFJ de Rotte","year":"2018","unstructured":"de Rotte MCFJ, Pluijm SMF, de Jong PHP et al (2018) Development and validation of a prognostic multivariable model to predict insufficient clinical response to methotrexate in rheumatoid arthritis. PLoS ONE. https:\/\/doi.org\/10.1371\/journal.pone.0208534","journal-title":"PLoS ONE"},{"key":"656_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2012\/978396","volume":"2012","author":"KI Halilova","year":"2012","unstructured":"Halilova KI, Brown EE, Morgan SL et al (2012) Markers of treatment response to methotrexate in rheumatoid arthritis: where do we stand? Int J Rheumatol 2012:1\u20137. https:\/\/doi.org\/10.1155\/2012\/978396","journal-title":"Int J Rheumatol"},{"key":"656_CR15","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-203723","author":"M Bulatovi\u0107 \u0106alasan","year":"2015","unstructured":"Bulatovi\u0107 \u0106alasan M, den Boer E, de Rotte MCFJ et al (2015) Methotrexate polyglutamates in erythrocytes are associated with lower disease activity in juvenile idiopathic arthritis patients. Ann Rheum Dis. https:\/\/doi.org\/10.1136\/annrheumdis-2013-203723","journal-title":"Ann Rheum Dis"},{"key":"656_CR16","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1136\/annrheumdis-2013-203725","volume":"74","author":"MCFJ De Rotte","year":"2015","unstructured":"De Rotte MCFJ, Den Boer E, De Jong PHP et al (2015) Methotrexate polyglutamates in erythrocytes are associated with lower disease activity in patients with rheumatoid arthritis. Ann Rheum Dis 74:408\u2013414. https:\/\/doi.org\/10.1136\/annrheumdis-2013-203725","journal-title":"Ann Rheum Dis"},{"key":"656_CR17","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.131290","author":"E den Boer","year":"2014","unstructured":"den Boer E, de Rotte MCJF, Pluijm SMF et al (2014) Determinants of erythrocyte methotrexate polyglutamate levels in rheumatoid arthritis. J Rheumatol. https:\/\/doi.org\/10.3899\/jrheum.131290","journal-title":"J Rheumatol"},{"key":"656_CR18","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1186\/s12876-022-02439-y","volume":"22","author":"MM van de Meeberg","year":"2022","unstructured":"van de Meeberg MM, Seinen ML, Fidder HH et al (2022) Subcutaneous administration, higher age and lower renal function are associated with erythrocyte methotrexate accumulation in Crohn\u2019s disease: a cross-sectional study. BMC Gastroenterol 22:365. https:\/\/doi.org\/10.1186\/s12876-022-02439-y","journal-title":"BMC Gastroenterol"},{"key":"656_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s13550-019-0505-x","author":"MC Schimmelpennink","year":"2019","unstructured":"Schimmelpennink MC, Vorselaars ADM, Veltkamp M, Keijsers RGM (2019) Quantification of pulmonary disease activity in sarcoidosis measured with 18F-FDG PET\/CT: SUVmax versus total lung glycolysis. EJNMMI Res. https:\/\/doi.org\/10.1186\/s13550-019-0505-x","journal-title":"EJNMMI Res"},{"key":"656_CR20","doi-asserted-by":"publisher","DOI":"10.1097\/MCP.0000000000000410","author":"AL Bakker","year":"2017","unstructured":"Bakker AL, Grutters JC, Keijsers RG, Post MC (2017) Cardiac sarcoidosis: challenges in clinical practice. Curr Opin Pulm Med. https:\/\/doi.org\/10.1097\/MCP.0000000000000410","journal-title":"Curr Opin Pulm Med"},{"key":"656_CR21","doi-asserted-by":"publisher","DOI":"10.1055\/s-0034-1376866","author":"H Adams","year":"2014","unstructured":"Adams H, Keijsers RG, Korenromp IHE, Grutters JC (2014) FDG PET for gauging of sarcoid disease activity. Semin Respir Crit Care Med. https:\/\/doi.org\/10.1055\/s-0034-1376866","journal-title":"Semin Respir Crit Care Med"},{"key":"656_CR22","doi-asserted-by":"publisher","first-page":"e26","DOI":"10.1164\/rccm.202002-0251ST","volume":"201","author":"ED Crouser","year":"2020","unstructured":"Crouser ED, Maier LA, Wilson KC et al (2020) Diagnosis and detection of sarcoidosis. An official American Thoracic Society clinical practice guideline. Am J Respir Crit Care Med 201:e26\u2013e51. https:\/\/doi.org\/10.1164\/rccm.202002-0251ST","journal-title":"Am J Respir Crit Care Med"},{"key":"656_CR23","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2016-000363","volume":"3","author":"C Takahashi","year":"2017","unstructured":"Takahashi C, Kaneko Y, Okano Y et al (2017) Association of erythrocyte methotrexate-polyglutamate levels with the efficacy and hepatotoxicity of methotrexate in patients with rheumatoid arthritis: a 76-week prospective study. RMD Open 3:e000363. https:\/\/doi.org\/10.1136\/rmdopen-2016-000363","journal-title":"RMD Open"},{"key":"656_CR24","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1007\/s00216-012-6581-7","volume":"405","author":"E den Boer","year":"2013","unstructured":"den Boer E, Meesters RJW, van Zelst BD et al (2013) Measuring methotrexate polyglutamates in red blood cells: a new LC-MS\/MS-based method. Anal Bioanal Chem 405:1673\u20131681. https:\/\/doi.org\/10.1007\/s00216-012-6581-7","journal-title":"Anal Bioanal Chem"},{"key":"656_CR25","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1148\/radiol.2016142043","volume":"280","author":"O Jh","year":"2016","unstructured":"Jh O, Lodge MA, Wahl RL (2016) Practical PERCIST: a simplified guide to PET response criteria in solid tumors 1.0. Radiology 280:576\u2013584. https:\/\/doi.org\/10.1148\/radiol.2016142043","journal-title":"Radiology"},{"key":"656_CR26","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s00259-017-3687-3","volume":"44","author":"K Pinker","year":"2017","unstructured":"Pinker K, Riedl C, Weber WA (2017) Evaluating tumor response with FDG PET: updates on PERCIST, comparison with EORTC criteria and clues to future developments. Eur J Nucl Med Mol Imaging 44:55\u201366. https:\/\/doi.org\/10.1007\/s00259-017-3687-3","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"656_CR27","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1002\/cpdd.279","volume":"6","author":"M Fischer","year":"2017","unstructured":"Fischer M, Siva S, Cook GK et al (2017) Methotrexate polyglutamate monitoring in patients with Crohn\u2019s disease. Clin Pharmacol Drug Dev 6:240\u2013245. https:\/\/doi.org\/10.1002\/cpdd.279","journal-title":"Clin Pharmacol Drug Dev"},{"key":"656_CR28","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/s41584-020-0373-9","volume":"16","author":"BN Cronstein","year":"2020","unstructured":"Cronstein BN, Aune TM (2020) Methotrexate and its mechanisms of action in inflammatory arthritis. Nat Rev Rheumatol 16:145\u2013154. https:\/\/doi.org\/10.1038\/s41584-020-0373-9","journal-title":"Nat Rev Rheumatol"},{"key":"656_CR29","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.1002\/art.24653","volume":"60","author":"LK Stamp","year":"2009","unstructured":"Stamp LK, O\u2019Donnell JL, Chapman PT et al (2009) Determinants of red blood cell methotrexate polyglutamate concentrations in rheumatoid arthritis patients receiving long-term methotrexate treatment. Arthritis Rheum 60:2248\u20132256. https:\/\/doi.org\/10.1002\/art.24653","journal-title":"Arthritis Rheum"},{"key":"656_CR30","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2974","author":"RCF Hebing","year":"2023","unstructured":"Hebing RCF, Bartelink IH, Gosselt H et al (2023) Methotrexate polyglutamates exposure\u2014response modeling in a large cohort of rheumatoid arthritis patients starting methotrexate. Clin Pharmacol Ther. https:\/\/doi.org\/10.1002\/cpt.2974","journal-title":"Clin Pharmacol Ther"},{"key":"656_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.113074","volume":"150","author":"Z Zhao","year":"2022","unstructured":"Zhao Z, Hua Z, Luo X et al (2022) Application and pharmacological mechanism of methotrexate in rheumatoid arthritis. Biomed Pharmacother 150:113074. https:\/\/doi.org\/10.1016\/j.biopha.2022.113074","journal-title":"Biomed Pharmacother"},{"key":"656_CR32","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-014-0179-5","author":"S Pan","year":"2014","unstructured":"Pan S, Stamp LK, Duffull SB et al (2014) Assessment of the relationship between methotrexate polyglutamates in red blood cells and clinical response in patients commencing methotrexate for rheumatoid arthritis. Clin Pharmacokinet. https:\/\/doi.org\/10.1007\/s40262-014-0179-5","journal-title":"Clin Pharmacokinet"},{"key":"656_CR33","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9030890","author":"RGM Keijsers","year":"2020","unstructured":"Keijsers RGM, Grutters JC (2020) In which patients with sarcoidosis is FDG PET\/CT indicated? J Clin Med. https:\/\/doi.org\/10.3390\/jcm9030890","journal-title":"J Clin Med"},{"key":"656_CR34","doi-asserted-by":"publisher","first-page":"321","DOI":"10.31083\/j.rcm.2020.03.102","volume":"21","author":"E Markatis","year":"2020","unstructured":"Markatis E, Afthinos A, Antonakis E, Papanikolaou IC (2020) Cardiac sarcoidosis: diagnosis and management. Rev Cardiovasc Med 21:321. https:\/\/doi.org\/10.31083\/j.rcm.2020.03.102","journal-title":"Rev Cardiovasc Med"}],"container-title":["Lung"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00408-023-00656-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00408-023-00656-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00408-023-00656-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,24]],"date-time":"2023-11-24T12:07:43Z","timestamp":1700827663000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00408-023-00656-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,16]]},"references-count":34,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["656"],"URL":"https:\/\/doi.org\/10.1007\/s00408-023-00656-0","relation":{},"ISSN":["0341-2040","1432-1750"],"issn-type":[{"value":"0341-2040","type":"print"},{"value":"1432-1750","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,16]]},"assertion":[{"value":"11 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}